What drugs does CAPLIN ONE LABS make?

CAPLIN ONE LABS has 4 FDA-approved drugs.

What therapeutic areas does CAPLIN ONE LABS focus on?

CAPLIN ONE LABS focuses primarily on Oncology and Immunology.

← Back

Data updated: Jun 28, 2026

CAPLIN ONE LABS

Pharma

Oncology Immunology

CAPLIN ONE LABS is a pharmaceutical company focused on Oncology, Immunology.

2006

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

CAPLIN ONE LABS's Key Drugs

CAPLIN ONE LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CAPLIN ONE LABS's Recent FDA Approvals

CAPLIN ONE LABS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BORTEZOMIB NDA

2024-08-26

bortezomib

1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

CAPLIN ONE LABS's Therapeutic Areas

CAPLIN ONE LABS's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 50%

1 drugs

Immunology 50%

1 drugs

CAPLIN ONE LABS's Top Competitors

CAPLIN ONE LABS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma

Oncology, Immunology

GSK big-pharma

Oncology, Immunology